Nautilus Biotechnology (NAUT)
(Delayed Data from NSDQ)
$2.58 USD
0.00 (0.00%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $2.55 -0.03 (-1.16%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Nautilus Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 173 | 184 | 346 | 1 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 3 | 3 | 0 | NA |
Total Current Assets | 177 | 187 | 349 | 1 | NA |
Net Property & Equipment | 4 | 4 | 2 | 0 | NA |
Investments & Advances | 91 | 129 | 16 | 150 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 1 | 1 | 0 | NA |
Total Assets | 306 | 350 | 398 | 151 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 1 | 2 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 4 | 4 | 3 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 9 | 7 | 6 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 5 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 140 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 40 | 35 | 35 | 146 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 468 | 455 | 444 | 6 | NA |
Retained Earnings | -202 | -139 | -81 | -1 | NA |
Other Equity | 0 | -2 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 265 | 315 | 364 | 5 | NA |
Total Liabilities & Shareholder's Equity | 306 | 350 | 398 | 151 | NA |
Total Common Equity | 265 | 315 | 364 | 5 | 0 |
Shares Outstanding | 124.90 | 124.70 | 124.10 | 16.70 | NA |
Book Value Per Share | 2.12 | 2.53 | 2.93 | 0.30 | 0.00 |
Fiscal Year End for Nautilus Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 181 | 173 | 183 | 163 | 167 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 4 | 3 | 3 |
Total Current Assets | 185 | 177 | 187 | 167 | 170 |
Net Property & Equipment | 5 | 4 | 4 | 4 | 4 |
Investments & Advances | 66 | 91 | 92 | 123 | 135 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 2 | 1 |
Total Assets | 289 | 306 | 318 | 331 | 346 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 4 | 3 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 9 | 9 | 8 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 39 | 40 | 41 | 41 | 42 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 471 | 468 | 465 | 461 | 458 |
Retained Earnings | -221 | -202 | -185 | -169 | -154 |
Other Equity | -1 | 0 | -2 | -2 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 249 | 265 | 277 | 290 | 304 |
Total Liabilities & Shareholder's Equity | 289 | 306 | 318 | 331 | 346 |
Total Common Equity | 249 | 265 | 277 | 290 | 304 |
Shares Outstanding | 125.20 | 124.90 | 124.90 | 124.80 | 124.80 |
Book Value Per Share | 1.99 | 2.12 | 2.22 | 2.32 | 2.43 |